Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesChemotherapy DrugsHCPCS hcpcs-j9020-asparaginase-injection-10000-units
    Ask Trek AI about this page

    HCPCS J9020: Asparaginase Injection, 10,000 Units

    Commercial payers pay $62 on average nationally for this procedure.

    HCPCS Level II code J9020 describes an injection of asparaginase, supplied as 10,000 units, used as a chemotherapeutic agent; the service is administration of the medication, typically delivered in an infusion or injection setting such as an outpatient oncology clinic or hospital infusion center.

    Customize your policy alerts

    Sign up for hcpcs J9020 policy alerts

    Get alerted when payer policies referencing J9020 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial rates for J9020 cluster around BUCA’s average commercial benchmark of $61.8, with notable variation among major insurers. Blue Cross Blue Shield centers near its own high mean of $62.0 and a median of $65.8, while Cigna and UnitedHealth Group sit well above BUCA’s average with means of $76.4 and $83.4 respectively; Cigna’s median is $77.9 and UnitedHealth Group’s median is $77.5. Aetna is materially lower, with a mean of $25.0 and a median of $12.4, indicating a distinct lower-cost segment in the market.

    Dispersion measured by the interquartile range (P75 minus P25) is tightest for Blue Cross Blue Shield at $12.2 (P75 $67.9 minus P25 $56.7) and for Cigna at $16.3 (P75 $84.3 minus P25 $67.0). The widest spread appears with UnitedHealth Group at $10.9 (P75 $81.9 minus P25 $73.1) and BUCA shows a spread of $15.9 (P75 $69.1 minus P25 $53.1). Aetna’s spread is $36.4 (P75 $44.9 minus P25 $8.6), the most pronounced variability among the listed payers.

    Table of contents

    Progress1 / 8

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 10-year-old child with newly diagnosed precursor B-cell acute lymphoblastic leukemia (ALL) is admitted to the pediatric oncology infusion center for induction chemotherapy. The treatment protocol calls for systemic asparaginase to reduce circulating asparagine and target leukemic blasts. The medication is supplied as multi-dose vials and dosed in units; the billed HCPCS Level II code is J9020 per 10,000 units. The clinical workflow includes verification of diagnosis and current weight, pharmacy compounding and dose calculation, allergy and prior reaction review, baseline laboratory assessment (including liver function tests, coagulation studies, and serum amylase/lipase), venous access confirmation (central line or peripheral IV), and administration under oncology nursing supervision with observation for hypersensitivity or pancreatitis. Documentation includes medication lot numbers, units administered, start and stop times, infusion site, premedications if any, and any adverse events. Billing uses J9020 with appropriate diagnosis C91.00, C91.01, or C91.02 as clinically indicated. Typical site of service is an outpatient oncology infusion center, though inpatient administration is possible for severe disease or complications. Common scenarios include induction therapy for ALL, consolidation or maintenance phases, and treatment of relapsed disease where asparaginase is indicated.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    23Modifier -23 (Unusual Anesthesia) is used on anesthesia service CPT codes when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia…- Use modifier -23 only on anesthesia CPT codes (00100–01999) when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia because of…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    54Modifier ‑54 (“Surgical care only”) is appended to a CPT surgical procedure when the reporting surgeon performs the intraoperative (surgical) component but does not furnish the preoperative and/or…- Use modifier -54 when the reporting surgeon provided only the intraoperative (surgical) component of a procedure and preoperative and/or postoperative management has been or will be provided by…
    55Modifier –55 indicates the billing provider furnished only postoperative management for a procedure that has a global surgical period. According to AAPC, this modifier is appended to the same CPT…- Use modifier -55 when billing the same CPT surgical code that has a 10- or 90-day global period and you, as a provider other than the original surgeon, furnished ONLY postoperative management (no…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0003X
    207RX0202X
    208D00000X
    2080P0205X
    101YM0800X
    103T00000X
    374U00000X
    163WC0400X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    C91.00Acute lymphoblastic leukemia not having achieved remission
    C91.01Acute lymphoblastic leukemia, in remission
    C91.02Acute lymphoblastic leukemia, in relapse
    C91.50Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission
    C91.51Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission
    C91.52Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse
    C92.00Acute myeloblastic leukemia, not having achieved remission
    C92.01Acute myeloblastic leukemia, in remission
    C94.00Acute erythroid leukemia, not having achieved remission
    C94.01Acute erythroid leukemia, in remission

    Showing 1–10 of 29

    Related Codes

    HCPCS-J9000-DOXORUBICIN-10MG-INJECTION

    HCPCS J9000: Doxorubicin Hydrochloride Injection, 10 mg

    HCPCS-J9003-LEUPROLIDE-INJECTABLE-CAMCEVI-1MG

    HCPCS Level II J9003: Leuprolide injectable (camcevi etm), 1 mg

    HCPCS-J9010-ALEMTUZUMAB-INJECTION-10MG

    HCPCS Level II J9010: Injection, alemtuzumab, 10 mg

    HCPCS-J9011-DATOPOTAMAB-DERUXTECAN-INJECTION-1MG

    HCPCS J9011: Datopotamab Deruxtecan Injection, 1 mg

    HCPCS-J9015-ALDESLEUKIN-INJECTION-SINGLE-USE-VIAL

    HCPCS Level II J9015: Aldesleukin Injection, Single-Use Vial

    HCPCS-J9017-ARSENIC-TRIOXIDE-INJECTION-1MG

    HCPCS J9017: Arsenic Trioxide Injection, 1 mg

    HCPCS-J9019-ASPARAGINASE-ERWINAZE-INJECTION-1000-IU

    HCPCS Level II J9019: Asparaginase (Erwinaze) Injection, 1,000 IU

    HCPCS-J9021-ASPARAGINASE-RYLAZE-INJECTION-0-1-MG

    HCPCS Level II J9021: Injection, asparaginase (Rylaze), 0.1 mg

    HCPCS-J9022-ATEZOLIZUMAB-INJECTION-10MG

    HCPCS J9022: Injection, atezolizumab 10 mg

    HCPCS-J9023-AVELUMAB-10MG-INJECTION

    HCPCS J9023: Avelumab Injection, 10 mg

    Showing 1–10 of 227

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    J9000Injection, doxorubicin hydrochloride, 10 mgAnother chemotherapeutic HCPCS drug code used in multi-agent regimens; may be administered in the same infusion visit as J9020 per protocol.
    J9027Injection, clofarabine, 1 mgAlternate antineoplastic agent used in certain leukemia regimens; may be administered before or after asparaginase depending on protocol.